京新药业：盐酸卡利拉嗪胶囊正在推进其审评工作，暂未收到批准上市的批文

Group 1 - The core point of the article is that Jingxin Pharmaceutical is currently advancing the review process for its hydrochloride carbilazone capsules and has not yet received approval for market launch [2] Group 2 - An investor inquired on the investor interaction platform about the status of the hydrochloride carbilazone capsule review, specifically whether the review stage has concluded and if they are awaiting approval [2] - Jingxin Pharmaceutical confirmed that the review work for the hydrochloride carbilazone capsules is ongoing and that they have not yet received the approval document for market launch [2]